Nifedipine
- Generic Name
- Nifedipine
- Brand Names
- Adalat, Afeditab CR, Nifediac, Nifedical, Procardia
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N2O6
- CAS Number
- 21829-25-4
- Unique Ingredient Identifier
- I9ZF7L6G2L
- Background
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is amlodipine.
Nifedipine was granted FDA approval on 31 December 1981.
- Indication
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
- Associated Conditions
- Achalasia, Chronic Stable Angina Pectoris, Fissure;Anal, Hypertension, Hypertensive Emergency, Premature Labour, Proctalgia, Pulmonary Edemas, Pulmonary Hypertension (PH), Raynaud's Phenomenon, Ureteral Calculus, Vasospastic Angina
Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 98
- Registration Number
- NCT02426177
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT02413515
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT02357615
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai, China
Oral Nifedipine Versus Oral Labetalol
- Conditions
- Severe Postpartum Hypertension
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT02168309
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Nifedipine for Acute Tocolysis of Preterm Labor
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 88
- Registration Number
- NCT02132533
- Locations
- 🇺🇸
Parkland Memorial Hospital, Dallas, Texas, United States
Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 20
- Registration Number
- NCT02090920
- Locations
- 🇺🇸
Eskenazi Health, Indianapolis, Indiana, United States
🇺🇸IU Health Methodist, Indianapolis, Indiana, United States
Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Reig Jofre Group
- Target Recruit Count
- 36
- Registration Number
- NCT02071589
- Locations
- 🇪🇸
CIM Sant Pau, Barcelona, Spain
Nifedipine Treatment on Uterine Contractility in IVF
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 90
- Registration Number
- NCT02072291
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Chantal Csajka
- Target Recruit Count
- 75
- Registration Number
- NCT02068404
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Bayer
- Registration Number
- NCT02047019
- Locations
- 🇮🇹
AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy
🇮🇹IRCCS Ist Neurologico Mediterraneo, Isernia, Molise, Italy
🇮🇹Fondazione Università G.D'Annunzio, Chieti, Abruzzo, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.